Getinge, a company that provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows, will acquire 100% of the shares in High Purity New England, Inc. (HPNE), a company involved in custom single-use solutions for bioprocessing applications.

Under terms of the deal, Getinge will acquire all outstanding shares from the shareholders of HPNE and will pay approximately $120 million. The transaction is expected to close in Q3 2023.

High Purity New England offers a range of proprietary and distributed products from drug discovery, upstream and downstream processing, to fill-and-finish. HPNE’s products assist biopharmaceutical and biotechnology players in the production of monoclonal antibodies, vaccines, cell and gene therapies, and other next-generation therapies.

According to Eric Honroth, president, life sciences at Getinge, the acquisition is another step in Getinge Life Science’s strategic journey to expand its presence in the biopharma segment. “High Purity New England (HPNE) has in recent years successfully supplied the industry with dedicated single use assemblies. We are delighted to join forces with HPNE providing our customers with comprehensive and innovative solutions for bioprocessing applications,” said Honroth.

“We are very excited to be joining the Getinge family. For over 20 years, High Purity New England has provided best-in-class products and solutions to the biopharmaceutical industry,” said Mark Sitcoske, founder and CEO of High Purity New England. “As we forge ahead into the next 20 years and beyond, I am thrilled to know that HPNE will continue to efficiently enable our customers to streamline and innovate their bioprocesses in combination with the Getinge name. Together, we will accomplish great things.”